logo-loader

Kazia Therapeutics substantial holder increases position

Published: 18:14 18 Mar 2020 EDT

Kazia Therapeutics Ltd - Kazia Therapeutics substantial holder grows position
Data from the study will be revealed at an upcoming cancer conference on 24-29 April 2020

Kazia Therapeutics Ltd (ASX:KZA) (NASDAQ:KZIA) substantial shareholder The Bank of New York Mellon Corporation has increased its shareholding to 28.54%.

A number of purchases throughout the month of March 2020 has grown the holding from 19.79 million shares to 20.59 million shares.

Trial recruitment recently completed

Kazia is an oncology-focused biotechnology company developing the drug paxalisib to treat brain cancer.

The company recently completed recruitment for the phase II clinical trial in newly-diagnosed glioblastoma (aggressive brain cancer).

30 patients were recruited at six sites in the US and the final patient commenced dosing on 27 February 2020.

Kazia has been accepted for a poster presentation at the upcoming American Association for Cancer Research (AACR) annual meeting in San Diego, CA on 24-29 April 2020.

ARway.ai announces multiple new SaaS developer contracts in both the United...

ARway.ai (CSE:ARWY, OTCQB:ARWYF) Chief Executive Officer Evan Gappelberg joined Steve Darling from Proactive to announce multiple new SaaS developer sign-ups for its augmented reality experience platform, focusing on AR indoor navigation. These partnerships represent significant milestones in...

36 minutes ago